Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Mesoblast ( (MESO) ) is now available.
On October 28, 2025, Mesoblast Limited announced a change in director’s interest and the issuance of new equity securities. William Burns, a director, acquired 120,000 ordinary shares through the exercise of options, increasing his total holdings. This move reflects Mesoblast’s ongoing efforts to strengthen its financial position and enhance shareholder value, potentially impacting its market standing and investor relations.
The most recent analyst rating on (MESO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score reflects a company with strong growth potential but significant financial challenges. The earnings call provided positive insights into future prospects, which are offset by current profitability issues and valuation concerns. Technical indicators suggest moderate positive momentum.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is an Australian company operating in the biotechnology industry, primarily focused on developing innovative cellular medicines. The company specializes in regenerative medicine, with a market focus on treating inflammatory diseases, cardiovascular conditions, and orthopedic disorders.
Average Trading Volume: 232,639
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.16B
For a thorough assessment of MESO stock, go to TipRanks’ Stock Analysis page.